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Objective: To determine the incidence of colon cancer in lung transplant recipients with cystic fibrosis (CF) and review screening colonoscopic
findings in other recipients with CF.
Methods: A retrospective chart review was performed for all patients with CF transplanted at the University of Wisconsin Hospital and Clinics
(January 1994 through December 2010).
Results: Four of 70 transplant recipients with CF developed fatal colon carcinoma following transplantation, and the cancer was advanced in all 4
recipients (age 31, 44, 44, 64) at the time of diagnosis. In contrast, only one of 287 recipients transplanted for non-CF indications developed colon
cancer. Of all recipients with CF who did not develop colon cancer, 20 recipients underwent screening colonoscopy at 1 to 12 years following
transplantation. Seven (35%) of the screened transplant recipients (ages 36, 38, 40, 41, 43, 49, 51) had colonic polyps in locations ranging from
cecum to sigmoid colon and up to 3 cm in diameter.
Conclusions: In contrast to non-CF recipients, patients with CF displayed a significant incidence of colon cancer (4 of 70 recipients; 5.7%) with
onset ranging from 246 days to 9.3 years post-transplant, which may be due to a combination of their underlying genetic disorder plus intense,
sustained immunosuppression following lung transplantation. Colonoscopic screening may identify patients with pre-malignant colonic lesions
and prevent progression to colonic malignancy.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Colon cancer; Cystic fibrosis; Lung transplant1. Introduction
Cystic fibrosis of the pancreas (CF) is a genetic disorder caused
by various mutations of the cystic fibrosis transmembrane
regulator (CFTR), which causes dysfunction of epithelial
membranes of the gastrointestinal and respiratory systems [1].
Most adults with CF will eventually develop advanced
bronchiectasis and respiratory insufficiency, and CF is the third
most common indication for which lung transplantation is⁎ Corresponding author at: Section of Allergy, Pulmonary and Critical Care
Medicine, Department of Medicine, University of Wisconsin School of Medicine
and Public Health, United States. Tel.: +1 608 263 6363 (office), +1 608 263 3035
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doi:10.1016/j.jcf.2011.05.003performed and the most common indication for bilateral lung
transplantation [2]. As more patients with severe CF lung disease
undergo lung transplantation, several issues that are somewhat
unique for this transplant indication can present significant
management issues [3,4]. These complications include diabetes
mellitus, liver disease, paranasal sinus disease, osteoporosis and
gastrointestinal dysfunction (pancreatic insufficiency, biliary tract
dysfunction, and impaired intestinal motility).
Colorectal cancer is the third most common malignancy
diagnosed in the general population of the United States, and it
ranks second in mortality [5]. The risk of gastrointestinal
malignancy has been reported to be increased in patients with
CF [6], and colonic adenocarcinoma has been reported in patients
ranging in age from 13 to 41 [7-11]. Sustained, intensed by Elsevier B.V. All rights reserved.
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lung transplant recipients. Although colonoscopy has been shown
to decrease the risk of colonic malignancy in the general
population by detecting pre-neoplastic polyps that can be
endoscopically removed [12-14], screening colonoscopy may
not be performed in relatively young patients with CF who
undergo lung transplantation. Guidelines for colorectal cancer
screening usually recommend the first screening at age 50 years
[12].2. Methods
We performed a retrospective chart review of all CF LTX
recipients with CF at University Hospital and Clinics who were
transplanted from 1994 through 2010. We identified all patients
who developed colon cancer, and we reviewed screening results
for all CF patients who had colonoscopies performed at various
time points post-transplant. This study was approved by the
University of Wisconsin Human Subjects Committee (Approval
#M-2008-1093).3. Results
Demographics of all patients (CF and non-CF indications)
transplanted at UWHC are given in Table 1. Four of the 70
recipients with CF followed by the University of Wisconsin
Hospital and Clinics from 1994 to 2008 developed metastatic
cancer of colonic origin, and none of these individuals had
undergone colonoscopic screening (Table 2). In contrast, only one
patient transplanted for other indications (N=287) through
December 2010 had developed colon cancer. Three of the 4
recipients with CF were under age 50 years at the time they
developed bowel symptoms and were diagnosed with colon
cancer. Diagnoses were made after the onset of abdominal
symptoms in all 4 patients, and diagnostic studies consisted of
radiologic imaging and colonoscopy in all. All patients who
developed colon cancer were receiving tacrolimus as their
calcineurin inhibitor from the time of transplant, and all had
enjoyed good lung allograft function up to the time of the onset of
symptoms and the diagnosis of colon cancer. Colon cancer was the
cause of death in 4 of the 33 recipients (12.1%) with CF who died
during the study period. In comparison, 14 recipients succumbed
to bronchiolitis obliterans syndrome (BOS), 7 to infection, 3 to
renal failure, and one each to primary graft dysfunction, acute
surgical complications (anastomotic dehiscence), post-transplant
lymphoproliferative disease, acute cerebrovascular infarction,
sudden cardiac death, and accidental death.Table 1
Characteristics of CF and non-CF recipients transplanted at UWHC.
Parameter CF Non-CF
Total recipients (N) 70 276/134
Gender (M/F) 37/33 141/146
Mean age (range ) 31.5 (17–55) 47 (14–74)
Kaplan–Meier survival (5 yr) 64% 61%
Colon cancer (N) 4 1When the third patient with colonic adenocarcinoma was
diagnosed, we recommended post-transplant colonoscopic
screening for all recipients with CF who were willing to give
consent for such. Colonic polyps were identified in 7 of the 20
(35%) recipients who underwent screening colonoscopy at
various time intervals ranging from 1 to 12 years after undergoing
lung transplantation (Table 3). One patient had 7 polyps at the first
screening procedure including a 3 cm diameter sessile tubulo-
villous adenoma, and this patient had another polyp at repeat
colonoscopy 425 days following the first procedure, and 8 new
polyps were found 337 days following the second colonoscopy.
All seven patients in whom polyps were identified had multiple
polyps, and two other patients had tubulovillous adenomas up to
1 cm diameter.
4. Discussion
Patients with CF can develop numerous GI complications that
are linked to CFTR dysfunction. These include complications of
intestinal dysmotility (gastric bezoars, distal intestinal obstruction
syndrome), biliary tract dysfunction (gastroesophageal reflux,
mucosal ulcerations, hepatic cirrhosis, cholelithiasis, cholecysti-
tis, biliary obstruction, acute pancreatitis, pseudomonas colitis,
fatty liver), and gastrointestinal malignancy [15-20]. These
potential complications can complicate the post-transplant course
of patients and cause significant morbidity or death, and the
immunosuppressive drug regimen that recipients must receive to
prevent allograft rejection can cause adverse GI reactions (nausea,
diarrhea) or increase the risk of infectious complications (enteric
cytomegalovirus infection, pseudomembranous colitis, other GI
tract infection).
It is estimated that 20–35% of the general populationwill have
a colorectal adenoma detected at age 50 or beyond [14], and 20–
50% of these individuals will have additional lesions detected at
followup examinations performed within 3–5 years of the initial
colonoscopy [14]. The presence of colorectal adenomas predicts
an increased risk of developing colorectal cancer [14], and it is
widely accepted that colon adenocarcinomas arise via conversion
of a subset of adenomas to cancerous lesions [14,21-24].
Although the overall incidence ofmalignant disease in patients
with CF has been reported to be within the expected range [24],
patients with CF appear to have an increased risk of developing
gastrointestinal malignancies [6,24]. Patients of age 13, 18, 30,
31, 31, and 41 at the time of diagnosis of colon cancer have been
reported in the medical literature [7-11]. The risk for developing
colon cancer at a young age may be increased for lung transplant
recipients with CF due to impaired tumor surveillance as a
consequence of the intense immunosuppression required to
prevent lung allograft rejection. In contrast to our recipients
with CF, only one of our non-CF recipients has been diagnosed
with colon cancer.
5. Summary and conclusions
Carcinoma of colonic origin can be a devastating complication
following successful bilateral lung transplantation for end-stage
lung disease in patients with CF. Four of 65 (6.2%) lung
Table 2
Characteristics of CF recipients with colon cancer.
Patient 1 2 3 4
Age at diagnosis 31 44 64 45
Gender Male Male Female Male
Time post-transplant (days) 246 493 3398 2438
Location Sigmoid colon Colorectal Colorectal; metastatic to liver Colorectal; metastatic to liver
Type of therapy Resection & chemotherapy Chemotherapy Ileostomy & chemotherapy Chemotherapy
Survival post-diagnosis (days) 430 568 255 76
Table 3
Characteristics of patients (no malignancy) with positive findings at colonoscopic screening.
Patient Age Sex Time post-TX
(days)
Colonic polyps Other findings Intervention
Number Location
1 41 F 4357 16* AC, DC, SC None Polypectomy
2 38 M 2986 None Diverticulosis in SC Fiber rich diet
3 40 M 3043 2 Left colon None Polypectomy
4 30 M 2344 None Anus Extensive anal & perianal condylomata Excision and fulguration of lesions
5 38 F 1666 2 Left colon None Polypectomy
6 51 M 1723 2 Cecum, SC Multiple fecoliths Polypectomy
7 43 M 1253 2 Mid/Proximal TC None Polypectomy
8 36 M 3190 2 AC, Cecum None Polypectomy
9 49 F 3447 11 Cecum, AC, SC None Polyps removed
*7 polyps (including 3 cm sessile tubulovillous adenoma)were found at initial screening colonoscopy; and additional 9 polypswere found on 2 subsequent followup procedures.
Abbreviations: AC=ascending colon; DC=descending colon; SC=sigmoid colon; TC=transverse colon; TX=transplant.
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beyond 6 months post-transplant developed fatal colonic adeno-
carcinomas, and 7 of 20 recipients (35%) who underwent
screening colonoscopy had polyps that ranged from 2 to 30 mm
in diameter. We suggest that lung transplant programs should
consider early (and perhaps sequential), screening colonoscopy
regardless of age for adult patients with CF following lung
transplantation to detect and remove pre-malignant lesions.
Individuals found to have colonic polyps at screening colonos-
copy should likely have more frequent followup colonoscopic
procecdures, as these individuals may be at considerable risk to
develop additional adenomas that may undergo malignant
transformation.References
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